


FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4



HSA #
§§§
###
§§
αSMA mRNA level
2.5
2.0
1.5
1.0
0.5
0.0
CSAA
Ctrl
3
GFT505
10
OCA
3
GFT505
+ OCA 10
CDAA + 1% cholesterol
HSA ##
§§§
###
§§
TIMP1 mRNA level
2.0
1.5
1.0
0.5
0.0
CSAA
Ctrl
3
GFT505
10
OCA
3
GFT505
+ OCA 10
CDAA + 1% cholesterol

FIGURE 5




FIGURE 5 (CONT.)

FIGURE 6




FIGURE 7




FIGURE 8





A
Experimental % inhibition
Cenicriviroc
Bezafibrate
[µM] 0 0,31 0,6 1 2,50 5 10
0 0 0 0 0 0 0 0
1,25 0 -11 -9 -3 -17 -2 -3
2,5 0 -15 -17 -10 -10 -8 -11
5 0 -5 7 -7 2 5 5
10 0 -13 -9 -3 -13 -10 -4
20 0 -12 0 -2 -6 -6 -3
% inhibition
Min Max
B
Excess over Bliss
Cenicriviroc
Bezafibrate
[µM] 0 0,31 0,63 1,25 2,5 5 10
0 - - - - - - -
1,25 - -11 -9 -3 -17 -2 -3
2,5 - -15 -17 -10 -10 -8 -11
5 - -5 7 -7 2 5 5
10 - -13 -9 -3 -13 -10 -4
20 - -12 0 -2 -6 -6 -3
Total EOB score -190
Min Max

FIGURE 9


A. MSDC-0602




B. PXS-4728A (BI-1467335)




C. Apararenone




D. CF-102 (Namodenoson)




E. Vismodegib



F. PBI-4050



G. Emricasan



H. DUR-928




FIGURE 10



EOB = 29
*
*
% inhibition of collagen production
70
60
50
40
30
20
10
0
Elafibranor 0,3µM
CP-640186 0,3µM
Elafibranor 0,3µM + CP-640186 0,3µM
EOB = 50
*
**
% inhibition over collagen production
70
60
50
40
30
20
10
0
-10
Elafibranor 0,3µM
GS-0976 0,3µM
Elafibranor 0,3µM + GS-0976 0,3µM
EOB = 32
*
***
%inhibition of collagen production
70
60
50
40
30
20
10
0
Elafibranor 3µM
Nalmefene 1µM
Elafibranor 3µM + Nalmefene 1µM

FIGURE 11



EOB = 17
**
**
60
40
20
0
% inhibition TNFa
ELA 1uM
gemcaben 62.5uM
ELA 1uM + gemcaben 62.5uM

FIGURE 12



EOB : 10
% inhibition of fat accumulation
100
10
1
GFT505 0.3µM
CP640186 1µM
GFT505 0.3µM CP640186 1µM
EOB : 12
% inhibition of fat accumulation
100
10
1
GFT505 3µM
VK2809 3 nM
GFT505 3µM VK2809 3nM
EOB : 10
% inhibition of fat accumulation
40
30
20
10
0
GFT505 10µM
Apa 0.03µM
GFT505 10µM Apa 0.03µM
EOB : 3
% inhibition of fat accumulation
50
40
30
20
10
0
GFT505 10µM
Aram 10µM
GFT505 10µM Aram 10µM

FIGURE 13



EOB 20
*
***
% inhibiton of lipid accumulation
45
40
35
30
25
20
15
10
5
0
ELA 3µM
MGL3196 1µM
ELA 3µM + MGL3196 1µM

FIGURE 14



A
Fibrosis surface (%)
B
Collagen (mg / g liver)
C
PIIINP (pg/ml)
D
TIMP-1 (pg/ml)
HSA
CSAA
Ctrl
GFT505
SEL
GFT505 + SEL 30
CD/FF

FIGURE 14 (CONT.)




FIGURE 14 (CONT.)




FIGURE 15




A
Fibrosis surface (%)
HSA ¤
¤¤¤
¤¤¤
¤¤
¤¤¤
CSAA
Ctrl
3
GFT505
60
GKT
3
GFT505 + GKT 60
CD/FF
B
Number of inflammatory foci
HSA ¤
¤¤¤
¤¤
¤¤¤
CSAA
Ctrl
1
GFT505
60
GKT
1
GFT505 + GKT 60
CD/FF
C
NAFLD activity score
HSA ¤
¤¤¤
¤¤
¤¤
CSAA
Ctrl
1
GFT505
60
GKT
1
GFT505 + GKT 60
CD/FF

FIGURE 16


A
$$$
$$$
HSA $$
$$$
Steatosis (grade)
0
1
2
3
4
CSAA
Ctrl
1
GFT505
30
GS
1
GFT505 + GS 30
CD/FF
B
¤¤
¤¤¤
HSA ¤¤¤
¤¤
¤¤¤
Triglycerides (mg/g of liver)
0
100
200
300
CSAA
Ctrl
1
GFT505
30
GS
1
GFT505 + GS 30
CD/FF
C
¤¤¤
HSA ¤¤
¤¤¤
¤
Body weight loss (%)
-10
0
10
20
30
40
Ctrl
1
GFT505
30
GS
1
GFT505 + GS 30
CD/FF